Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry-Reference-Cited by-同舟云学术

Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry

Published:2022-02-10 Issue:2 Volume:25 Page:314-319
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Wei Xiao X.^ORCID,Kwak Lucia,Hamid Anis,He Monica,Sweeney Christopher^ORCID,Flanders Scott C.,Harmon Matthew,Choudhury Atish D.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-022-00493-x.pdf

Reference33 articles.

1. Wei XX, Fong L, Small EJ. Prostate cancer immunotherapy with sipuleucel-T: current standards and future directions. Expert Rev Vaccines. 2015;14:1529–41.

2. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089–94.

3. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670–9.

4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl J Med. 2010;363:411–22.

5. Tannock IF, de Wit R, Berry WR, Horti J, Plunzanska A, Chi KM, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl J Med. 2004;351:1502–12.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. State‐of‐the‐art in transposable element modulation affected by drugs in malignant prostatic cancer cells;Journal of Cellular Biochemistry;2024-03-19

2. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies;Medical Oncology;2024-01-09

3. Microwave triggered multifunctional nanoplatform for targeted photothermal-chemotherapy in castration-resistant prostate cancer;Nano Research;2023-02-27

4. Macrophage-Mediated Cancer Immunology in Cutaneous Malignancies;Interdisciplinary Cancer Research;2023

5. Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells;International Journal of Molecular Sciences;2022-12-03